EYP-1901 History and Updates

26 events · 2021 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
26
Trial Milestones
0
Pivotal Publications
EYP-1901 — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications20212022202320242025202620272028Trial: NCT07449936 2026-02-16 → 2027-10-31 (primary completion)Trial: NCT07449923 2026-02-09 → 2027-10-31 (primary completion)Trial: NCT06683742 2024-11-27 → 2026-10-31 (primary completion)Trial: NCT06668064 2024-10-22 → 2026-08-31 (primary completion)Trial: NCT06099184 2024-01-15 → 2024-10-24 (primary completion)Trial: NCT05383209 2022-09-28 → 2024-02-12 (primary completion)Trial: NCT05381948 2022-06-30 → 2023-11-29 (primary completion)Trial: NCT04747197 2021-01-20 → 2022-05-11 (primary completion)Results posted — 2025-07-28 Trial results posted: NCT05383209 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)Results posted — 2025-10-02 Trial results posted: NCT05381948 Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)today (2026-06-04)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-04Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for EYP-1901 since 2021, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (2)

2025

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06668064
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT06683742
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07449923
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07449936
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Past events

2026
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07449936
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07449923
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025
2024
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT06683742
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT06668064
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week
2023
2022
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT04747197
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
2021
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT04747197
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.